Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian))

Written1998-03Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers France
Updated2012-02Tiangang Zhuang, Mayumi Higashi, Venkatadri Kolla, Garrett M Brodeur
Children's Hospital of Philadelphia, Oncology Research, CTRB Rm 3018, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA

(Note : for Links provided by Atlas : click)

Identity

Alias_namesNMYC
Alias_symbol (synonym)bHLHe37
N-myc
MYCNOT
Other aliasMODED
ODED
HGNC (Hugo) MYCN
LocusID (NCBI) 4613
Atlas_Id 112
Location 2p24.3  [Link to chromosome band 2p24]
Location_base_pair Starts at 15940438 and ends at 15947007 bp from pter ( according to hg19-Feb_2009)  [Mapping MYCN.png]
Local_order Centromeric to DDX1.
 
  Fluorescence in-situ hybridization of MYCN probe to metaphase and interphase nuclei of a primary neuroblastoma with MYCN amplification (Courtesy Garrett M. Brodeur, Children's Hospital of Philadelphia).
 
  MYCN (2p24). Fluorescence in-situ hybridization of MYCN probe to metaphase spread (Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics).
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
C17orf80 (17q25.1) / MYCN (2p24.3)MYCN (2p24.3) / GULP1 (2q32.1)SPATA48 (7p12.2) / MYCN (2p24.3)
STPG1 (1p36.11) / MYCN (2p24.3)

DNA/RNA

Description 3 exons.

Protein

Description 464 amino acids; contains a phosphorylation site, an acidic domain, an HLH motif, and a leucine zipper in C-term; forms heterodimers with MAX and binds to an E-box DNA recognition sequence. The consensus sequence for the E-box element is CANNTG, with a palindromic canonical sequence of CACGTG.
Expression MYCN is expressed in brain, eye, heart, kidney, lung, muscle, ovary, placenta and thymus. It is also expressed highly in several tumors: glioma, lung tumor, primitive neuroectodermal tumor, retinoblastoma (EST Profile).
Localisation Nuclear.
Function Probable transcription factor; possible role during tissue differentiation.
Homology With members of the myc family of helix-loop-helix transcription factors.

Mutations

Somatic Amplification, either in extrachromosomal double minutes (DMs) or in homogeneously staining regions within chromosomes (there is amplification when, for example, 10 to 1000 copies of a gene are present in a cell); found amplified in a variety of human tumors, in particular in neuroblastoma and also in retinoblastoma, small cell lung carcinoma, astrocytoma; level of amplification related to the tumor progression; transgenic mice that overexpress MYCN in neuroectodermal cells develop neuroblastoma.

Implicated in

Note
  
Entity Neuroblastoma
Note Neuroblastoma karyotypes frequently reveal the cytogenetic hallmarks of gene amplification, namely DMs or HSRs. Schwab (Schwab et al., 1983) and Kohl (Kohl et al., 1983) originally identified the MYC-related oncogene MYCN as the target of this amplification event. MYCN is located on the distal short arm of chromosome 2 (2p24), but in cells with MYCN amplification, the extra copies reside within these DMs or HSRs (Schwab et al., 1984). Additional genes may be coamplified with MYCN in a subset of cases (DDX1, NAG, ALK), but MYCN is the only gene that is consistently amplified from this locus. The magnitude of MYCN amplification varies, but it averages 100-200 copies per cell (range 5-500+ copies).
The overall prevalence of MYCN amplification is 18-20%. Amplification of MYCN is associated with advanced stages of disease, unfavorable biological features, and a poor outcome (Brodeur et al., 1984; Seeger et al., 1985), but it is also associated with poor outcome in otherwise favorable patient groups (such as infants, and patients with lower stages of disease), underscoring its biological importance (Seeger et al., 1985; Look et al., 1991; Tonini et al., 1997; Katzenstein et al., 1998; Bagatell et al., 2005; George et al., 2005; Schneiderman et al., 2008). Therefore, the status of the MYCN gene is routinely determined from neuroblastoma samples obtained at diagnosis to assist in therapy planning (Look et al., 1991; Schwab et al., 2004). Indeed, because of the dramatic degree of MYCN amplification and consequent overexpression in a subset of aggressive neuroblastomas, it should be an attractive therapeutic target (Pession and Tonelli, 2005; Bell et al., 2010).
Weiss and colleagues (Weiss et al., 1997) created a transgenic mouse model of neuroblastoma, with MYCN expression driven in adrenergic cells by the tyrosine hydroxylase promoter (TH-MYCN mouse). Genomic changes in neuroblastomas arising in TH-MYCN mice closely parallel the genomic changes found characteristically in human tumors (Hackett et al., 2003). Thus, the TH-MYCN mouse model appears to be a tractable model to study neuroblastoma development, progression and therapy (Chessler and Weiss, 2011).
  
  
Entity Medulloblastoma
Note MYCN amplification is less common in medulloblastoma, a neural brain tumor of childhood, but it is also associated with a worse clinical outcome (Pfister et al., 2009). However, recent evidence suggests that MYCN overexpression is much more common in medulloblastomas, compared to normal cerebellum (Swartling et al., 2010), and it may drive the initiation or progression of medulloblastomas independent of the sonic hedgehog (SHH) pathway. Indeed, MYCN amplification is found in both SHH-driven and non-SHH-driven medulloblastomas, but each subtype is associated with other genetic features, suggesting they represent genetically distinct subtypes with different prognoses (Korshunov et al., 2011).
  
  
Entity Rhabdomyosarcoma (RMS)
Note MYCN amplification also occurs in a subset of RMS, the most common pediatric soft tissue sarcoma, although it tends to be at a lower level (4-20 fold) than is found in neuroblastomas. Amplification is found predominantly in the alveolar subsest of RMS, and it is rarely found in the more common form, called embryonal RMS (Driman et al., 1994). However, MYCN expression is found in the vast majority of RMS tumors, regardless of histology, at least in primary tumors (Toffolatti et al., 2002). For this reason, Morgenstern and Anderson have suggested that it would be an attractive therapeutic target for this disease (Morgenstern and Anderson, 2006).
  
  
Entity Wilms tumor
Note Wilms tumor may occasionally show amplification of the MYCN protooncogene (Schaub et al., 2007). MYCN amplification is consistently associated with overexpression, at least at the mRNA level. Initially, MYCN amplification was associated almost exclusively with the unfavorable, anaplastic subset of Wilms tumors. However, Williams and colleagues (Williams et al., 2011) found focal gain of MYCN in a substantial number of both anaplastic and favorable histologies in a survey of over 400 tumors, suggesting that other genomic changes may account for differences in clinical behavior.
  
  
Entity Other tumors (retinoblastoma, small cell lung cancer, glioblastoma multiforme)
Note About 3-5% of primary retinoblastomas have MYCN amplification, whereas it is much more common (27%) in established retinoblastoma cell lines (Bowles et al., 2007; Kim et al., 2008). MYCN is amplified in 15-25% of small cell lung cancers, and it may be more common in tumors at relapse (Johnson et al., 1987; Johnson et al., 1992). MYCN amplification rarely occurs in other lung cancer histologies (Yokota et al., 1988). MYCN amplification occurs in a substantial number of glioblastoma multiformes (Hui et al., 2001; Hodgson et al., 2008), but it is rarely found in lower grade gliomas and astrocytomas.
  

Bibliography

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC.
J Clin Oncol. 2005 Dec 1;23(34):8819-27.
PMID 16314642
 
MYCN oncoprotein targets and their therapeutic potential.
Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.
Cancer Lett. 2010 Jul 28;293(2):144-57. Epub 2010 Feb 13. (REVIEW)
PMID 20153925
 
Profiling genomic copy number changes in retinoblastoma beyond loss of RB1.
Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL.
Genes Chromosomes Cancer. 2007 Feb;46(2):118-29.
PMID 17099872
 
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM.
Science. 1984 Jun 8;224(4653):1121-4.
PMID 6719137
 
Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.
Chesler L, Weiss WA.
Semin Cancer Biol. 2011 Oct;21(4):245-55. Epub 2011 Sep 21. (REVIEW)
PMID 21958944
 
MYCN gene amplification in rhabdomyosarcoma.
Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J.
Cancer. 1994 Apr 15;73(8):2231-7.
PMID 8156531
 
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.
J Clin Oncol. 2005 Sep 20;23(27):6466-73. Epub 2005 Aug 22.
PMID 16116152
 
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA.
Cancer Res. 2003 Sep 1;63(17):5266-73.
PMID 14500357
 
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.
Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD.
Neuro Oncol. 2009 Oct;11(5):477-87. Epub 2009 Jan 12.
PMID 19139420
 
Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization.
Hui AB, Lo KW, Yin XL, Poon WS, Ng HK.
Lab Invest. 2001 May;81(5):717-23.
PMID 11351043
 
myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer.
Johnson BE, Brennan JF, Ihde DC, Gazdar AF.
J Natl Cancer Inst Monogr. 1992;(13):39-43.
PMID 1327035
 
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL.
J Clin Oncol. 1998 Jun;16(6):2007-17.
PMID 9626197
 
N-myc amplification was rarely detected by fluorescence in situ hybridization in retinoblastoma.
Kim JH, Choi JM, Yu YS, Kim DH, Kim JH, Kim KW.
Hum Pathol. 2008 Aug;39(8):1172-5. Epub 2008 Jun 5.
PMID 18538370
 
Transposition and amplification of oncogene-related sequences in human neuroblastomas.
Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW.
Cell. 1983 Dec;35(2 Pt 1):359-67.
PMID 6197179
 
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Peter Collins V, Westermann F, Taylor MD, Lichter P, Pfister SM.
Acta Neuropathol. 2012 Apr;123(4):515-27. Epub 2011 Dec 9.
PMID 22160402
 
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM.
J Clin Oncol. 1991 Apr;9(4):581-91.
PMID 2066755
 
MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma.
Morgenstern DA, Anderson J.
Expert Rev Anticancer Ther. 2006 Feb;6(2):217-24. (REVIEW)
PMID 16445374
 
The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors.
Pession A, Tonelli R.
Curr Cancer Drug Targets. 2005 Jun;5(4):273-83. (REVIEW)
PMID 15975048
 
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A.
J Clin Oncol. 2009 Apr 1;27(10):1627-36. Epub 2009 Mar 2.
PMID 19255330
 
Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
Schaub R, Burger A, Bausch D, Niggli FK, Schafer BW, Betts DR.
Cancer Genet Cytogenet. 2007 Jan 1;172(1):61-5.
PMID 17175381
 
Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL.
J Clin Oncol. 2008 Feb 20;26(6):913-8.
PMID 18281664
 
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J.
Nature. 1983 Sep 15-21;305(5931):245-8.
PMID 6888561
 
MYCN in neuronal tumours.
Schwab M.
Cancer Lett. 2004 Feb 20;204(2):179-87. (REVIEW)
PMID 15013217
 
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D.
N Engl J Med. 1985 Oct 31;313(18):1111-6.
PMID 4047115
 
Pleiotropic role for MYCN in medulloblastoma.
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L.
Genes Dev. 2010 May 15;24(10):1059-72.
PMID 20478998
 
MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.
Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M, Carli M, Rosolen A.
J Pathol. 2002 Apr;196(4):450-8.
PMID 11920742
 
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B.
J Clin Oncol. 1997 Jan;15(1):85-93.
PMID 8996128
 
Targeted expression of MYCN causes neuroblastoma in transgenic mice.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM.
EMBO J. 1997 Jun 2;16(11):2985-95.
PMID 9214616
 
Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K.
Genes Chromosomes Cancer. 2011 Dec;50(12):982-95. doi: 10.1002/gcc.20907. Epub 2011 Aug 31.
PMID 21882282
 
Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes.
Yokota J, Wada M, Yoshida T, Noguchi M, Terasaki T, Shimosato Y, Sugimura T, Terada M.
Oncogene. 1988 Jun;2(6):607-11.
PMID 2838790
 

Citation

This paper should be referenced as such :
Zhuang, T ; Higashi, M ; Kolla, V ; Brodeur, GM
MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian))
Atlas Genet Cytogenet Oncol Haematol. 2012;16(7):488-491.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/NMYCID112.html
History of this paper:
Huret, JL. MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived). Atlas Genet Cytogenet Oncol Haematol. 1998;2(2):41-42.
http://documents.irevues.inist.fr/bitstream/handle/2042/37407/03-1998-NMYC112.pdf


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 2 ]
  t(7;19)(q34;p13) TRB/LYL1
t(8;14)(q24;q32) IGH/MYC::t(2;8)(p12;q24) IGK/MYC::t(8;22)(q24;q11) IGL/MYC


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 7 ]
  Nervous system: Astrocytic tumors
Bone: Conventional Osteosarcoma
Lung: small cell cancer
Nervous system: Peripheral neuroblastic tumours (Neuroblastoma, Ganglioneuroblastoma, Ganglioneuroma)
Ovary: Germ cell tumors
Head and neck: Retinoblastoma
Eye: Retinoma


External links

Nomenclature
HGNC (Hugo)MYCN   7559
Cards
AtlasNMYCID112
Entrez_Gene (NCBI)MYCN  4613  MYCN proto-oncogene, bHLH transcription factor
AliasesMODED; N-myc; NMYC; ODED; 
bHLHe37
GeneCards (Weizmann)MYCN
Ensembl hg19 (Hinxton)ENSG00000134323 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000134323 [Gene_View]  chr2:15940438-15947007 [Contig_View]  MYCN [Vega]
ICGC DataPortalENSG00000134323
TCGA cBioPortalMYCN
AceView (NCBI)MYCN
Genatlas (Paris)MYCN
WikiGenes4613
SOURCE (Princeton)MYCN
Genetics Home Reference (NIH)MYCN
Genomic and cartography
GoldenPath hg38 (UCSC)MYCN  -     chr2:15940438-15947007 +  2p24.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MYCN  -     2p24.3   [Description]    (hg19-Feb_2009)
EnsemblMYCN - 2p24.3 [CytoView hg19]  MYCN - 2p24.3 [CytoView hg38]
Mapping of homologs : NCBIMYCN [Mapview hg19]  MYCN [Mapview hg38]
OMIM164280   164840   189960   
Gene and transcription
Genbank (Entrez)AF320053 AI962624 AK298225 AK299495 BC002712
RefSeq transcript (Entrez)NM_001293228 NM_001293231 NM_001293233 NM_005378
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)MYCN
Cluster EST : UnigeneHs.25960 [ NCBI ]
CGAP (NCI)Hs.25960
Alternative Splicing GalleryENSG00000134323
Gene ExpressionMYCN [ NCBI-GEO ]   MYCN [ EBI - ARRAY_EXPRESS ]   MYCN [ SEEK ]   MYCN [ MEM ]
Gene Expression Viewer (FireBrowse)MYCN [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4613
GTEX Portal (Tissue expression)MYCN
Human Protein AtlasENSG00000134323-MYCN [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP04198   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP04198  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP04198
Splice isoforms : SwissVarP04198
PhosPhoSitePlusP04198
Domaine pattern : Prosite (Expaxy)BHLH (PS50888)   
Domains : Interpro (EBI)bHLH_dom    Tscrpt_reg_Myc    Tscrpt_reg_Myc_N   
Domain families : Pfam (Sanger)HLH (PF00010)    Myc_N (PF01056)   
Domain families : Pfam (NCBI)pfam00010    pfam01056   
Domain families : Smart (EMBL)HLH (SM00353)  
Conserved Domain (NCBI)MYCN
DMDM Disease mutations4613
Blocks (Seattle)MYCN
PDB (SRS)5G1X   
PDB (PDBSum)5G1X   
PDB (IMB)5G1X   
PDB (RSDB)5G1X   
Structural Biology KnowledgeBase5G1X   
SCOP (Structural Classification of Proteins)5G1X   
CATH (Classification of proteins structures)5G1X   
SuperfamilyP04198
Human Protein Atlas [tissue]ENSG00000134323-MYCN [tissue]
Peptide AtlasP04198
HPRD01278
IPIIPI00022372   IPI01009438   IPI00029523   IPI00921416   
Protein Interaction databases
DIP (DOE-UCLA)P04198
IntAct (EBI)P04198
FunCoupENSG00000134323
BioGRIDMYCN
STRING (EMBL)MYCN
ZODIACMYCN
Ontologies - Pathways
QuickGOP04198
Ontology : AmiGOchromatin  cartilage condensation  positive regulation of mesenchymal cell proliferation  DNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  nucleus  nucleolus  transcription, DNA-templated  regulation of transcription from RNA polymerase II promoter  positive regulation of gene expression  negative regulation of gene expression  positive regulation of cell death  lung development  embryonic digit morphogenesis  regulation of auditory receptor cell differentiation  positive regulation of transcription, DNA-templated  positive regulation of transcription from RNA polymerase II promoter  protein dimerization activity  embryonic skeletal system morphogenesis  negative regulation of astrocyte differentiation  branching morphogenesis of an epithelial tube  positive regulation of production of miRNAs involved in gene silencing by miRNA  negative regulation of reactive oxygen species metabolic process  
Ontology : EGO-EBIchromatin  cartilage condensation  positive regulation of mesenchymal cell proliferation  DNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  nucleus  nucleolus  transcription, DNA-templated  regulation of transcription from RNA polymerase II promoter  positive regulation of gene expression  negative regulation of gene expression  positive regulation of cell death  lung development  embryonic digit morphogenesis  regulation of auditory receptor cell differentiation  positive regulation of transcription, DNA-templated  positive regulation of transcription from RNA polymerase II promoter  protein dimerization activity  embryonic skeletal system morphogenesis  negative regulation of astrocyte differentiation  branching morphogenesis of an epithelial tube  positive regulation of production of miRNAs involved in gene silencing by miRNA  negative regulation of reactive oxygen species metabolic process  
Pathways : KEGGTranscriptional misregulation in cancer   
NDEx NetworkMYCN
Atlas of Cancer Signalling NetworkMYCN
Wikipedia pathwaysMYCN
Orthology - Evolution
OrthoDB4613
GeneTree (enSembl)ENSG00000134323
Phylogenetic Trees/Animal Genes : TreeFamMYCN
HOVERGENP04198
HOGENOMP04198
Homologs : HomoloGeneMYCN
Homology/Alignments : Family Browser (UCSC)MYCN
Gene fusions - Rearrangements
Fusion : MitelmanIGH/MYCN [14q32.33/2p24.3]  [t(2;14)(p24;q32)]  
Fusion : MitelmanMYCN/GULP1 [2p24.3/2q32.1]  [t(2;2)(p24;q32)]  
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMYCN [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MYCN
dbVarMYCN
ClinVarMYCN
1000_GenomesMYCN 
Exome Variant ServerMYCN
ExAC (Exome Aggregation Consortium)ENSG00000134323
GNOMAD BrowserENSG00000134323
Genetic variants : HAPMAP4613
Genomic Variants (DGV)MYCN [DGVbeta]
DECIPHERMYCN [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisMYCN 
Mutations
ICGC Data PortalMYCN 
TCGA Data PortalMYCN 
Broad Tumor PortalMYCN
OASIS PortalMYCN [ Somatic mutations - Copy number]
Cancer Gene: CensusMYCN 
Somatic Mutations in Cancer : COSMICMYCN  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDMYCN
intOGen PortalMYCN
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch MYCN
DgiDB (Drug Gene Interaction Database)MYCN
DoCM (Curated mutations)MYCN (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)MYCN (select a term)
intoGenMYCN
NCG5 (London)MYCN
Cancer3DMYCN(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM164280    164840    189960   
Orphanet548    22198    22197    22634    22634   
MedgenMYCN
Genetic Testing Registry MYCN
NextProtP04198 [Medical]
TSGene4613
GENETestsMYCN
Target ValidationMYCN
Huge Navigator MYCN [HugePedia]
snp3D : Map Gene to Disease4613
BioCentury BCIQMYCN
ClinGenMYCN (curated)
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD4613
Chemical/Pharm GKB GenePA31359
Drug Sensitivity MYCN
Clinical trialMYCN
Miscellaneous
canSAR (ICR)MYCN (select the gene name)
Other databasehttp://cancergenome.broadinstitute.org/index.php?tgene=MYCN
Probes
Litterature
PubMed315 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMYCN
EVEXMYCN
GoPubMedMYCN
iHOPMYCN
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 12 16:28:53 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.